[Effect of cerebrolysin on the electroencephalographic indices of brain activity in Parkinson's disease].
Cerebrolysin is a brain-derived peptide drug that increases the BBB-GLUT1 and MAP2 genes expression, thus exerting a neuroprotective effect. The present study aimed at investigating in patients with Parkinson's disease (PD) influence of Cerebrolysin infusions (intravenously, 10 ml during 10 days) combined with levodopa treatment on the electroencephalographic (EEG) indices of brain activity: P300 potential, contingent negative variation (CNV) and recovery functions of the cortical auditory evoked potentials, which reflect the postexcitatory inhibition at the paired stimulation. Nineteen PD patients, mean age 61.4 +/- 1.7 years; disease stage according to M.M. Hoehn and M.D. Yahr, 1967-2.2 +/- 0.1) and 18 age-matched healthy controls were studied. In the patients with essential differences of the EEG indices, comparing to the normal values, statistically significant changes were revealed: a decrease of P300 latency from 419.4 +/- 23.5 to 356.3 +/- 18.4 ms (8 patients, 42%); an increase of CNV duration from 423.1 +/- 93.3 to 600.6 +/- 38.5 ms; 2-fold increase of CNV mean amplitude and 3-fold increase of CNV square (8 patients, 42%) and strengthening of postexcitatory inhibition in auditory system at the paired stimulation (13 patients, 68%). In conclusion, Cerebrolysin may be recommended as an additional neuroprotective drug for brain functions improvement in the complex pathogenetic therapy of earlier PD stages.
Lukhanina
E P
EP
Karaban'
I N
IN
Burenok
Iu A
IuA
Mel'nik
N A
NA
Berezetskaia
N M
NM
D000368:Aged; D000596:Amino Acids / Q000627:therapeutic use*; D002230:Carbidopa / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004569:Electroencephalography; D005071:Evoked Potentials; D005260:Female; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D010300:Parkinson Disease / Q000188:drug therapy* / Q000503:physiopathology*; D016896:Treatment Outcome
D000596:Amino Acids; D018696:Neuroprotective Agents; C006952:cerebrolysin; D007980:Levodopa; D002230:Carbidopa